ClinicalTrials.gg
Active, not recruitingNCT04971772SIGNATUREUpdated Mar 19, 2026

SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries

An observational study in Peripheral Arterial Disease, Superficial Femoral Artery Stenosis and Angiopathy, Peripheral, sponsored by Cardionovum GmbH. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Cardionovum GmbH · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.

Enrollment
29th of 47
150 · median 200
Started
2022
with 13 others
Observational
47 of 173
5 open now
Primary completion
2026-12
later than 17 of 28 live
Registered
138th of 173
by date

Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 29th largest by enrollment of the 47 observational ones that give a count, is one of 14 that started in 2022, is one of 47 observational ones, reaches primary completion later than 17 of the 28 other live ones, and was the 138th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Peripheral Arterial Disease with a site in Germany, or all of them as a file.
02

Study summary

The aim of this study is to demonstrate the superiority in safety and efficacy of the Legflow DCB vs standard uncoated POBA in a randomized controlled (RCT) for treatment of patients with symptomatic peripheral artery disease (PAD) due to stenosis, restenosis or occlusion of the femoral and/or popliteal arteries.

03

Conditions studied

  • Peripheral Arterial Disease
  • Superficial Femoral Artery Stenosis
  • Angiopathy, Peripheral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with peripheral arterial disease in the SFA, eligible for treatment with the paclitaxel coated Legflow dilatation balloon catheter

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥18 years
  • Patient has Rutherford Classification 2,3 or4.
  • Patient has provided written and is willing to comply with study follow-up requirements.
  • De novo stenotic or occlusive lesion(s) or non-stented restenotic or occlusive lesion(s) occurring >90 days after prior plain old balloon (POBA) angioplasty or >180 days after prior DCB treatment.
  • Target lesion is located between the ostium of the SFA and the end of the P1 segment of the popliteal artery
  • Target vessel diameter ≥ 4 mm and ≤ 7 mm
  • Target lesion must be stenotic or occlusive lesion ≤ 150mm in length (one long lesion or tandem lesions) by investigator's visual estimate. [Note: tandem lesions must have a total length of ≤ 150 mm by visual estimate and be separated by ≤ 30 mm.]
  • Target lesion must have angiographic evidence of ≥ 70 % stenosis by investigator's visual estimation
  • Successful, uncomplicated crossing of the target lesion occurs when the tip of the guidewire is distal to the target lesion without the occurrence of flow-limiting dissection of perforation and is judged by visual inspection to be within the true lumen. Subintimal dissection techniques may be used if re-entry occurs above-the-knee (ATK) and without the use of re-entry devices.
  • Target lesion is located at least 30mm from any stent if target vessel was previously stented.
  • A patent inflow artery free from significant stenosis ((≥50% stenosis) as confirmed by angiography.
  • At least one patent native outflow artery to the ankle or foot, free from significant stenosis (≥ 50 % stenosis) as confirmed by angiography.

Exclusion criteria

Exclusion criteria:

  • Acute Limb Ischemia
  • Patient underwent an intervention involving the target vessel within the previous 90 days.
  • Patient underwent any lower extremity percutaneous treatment in the ipsilateral limb using plain old balloon (POBA) angioplasty within the previous 90 days.
  • Patient underwent a percutaneous transluminal angioplasty (PTA) of the target lesion using a DCB within the previous 180 days.
  • Pregnant women or women who are intending to become pregnant.
  • Patient has a of less than 1 year
  • Patient has a known allergy to contrast medium that cannot be adequately pre-medicated.
  • Patient is allergic to all anti- treatments
  • Patient is receiving therapy
  • Patient has platelet count \<100.000/mm3 or >700.000/mm
  • Patient has history of gastrointestinal hemorrhage requiring a transfusion within 3 months prior to the study procedure
  • Patient is diagnosed with coagulopathy that precludes treatment with systemic anticoagulation and/or dual antiplatelet therapy (DAPT)
  • Patient has history of stroke within past 90 days
  • Patient has history of myocardial infarction within the past 30 days.
  • Patient is participating in an drug or medical device study that has not completed primary endpoint(s) evaluation or that clinically interferes with the endpoints from this study.
  • Patient has had any major (e.g. cardiac, peripheral, abdominal) surgical procedure or intervention unrelated to this study within 30 days prior to the index procedure or has planned major surgical procedure or intervention within 30 days of the index procedure
  • An intervention in the contralateral limb, planned within 30 days post-index procedure
  • Patient had previous bypass surgery of the target lesion
  • Patient had previous treatment of the target vessel with thrombolysis or surgery
  • Patient is unwilling or unable to comply with procedures specified in the protocol or has difficulty or inability to return for follow-up visits as specified by the protocol
  • Target lesion involves an aneurysm or is adjacent to an aneurysm (within 5 mm)
  • Target Lesion requires treatment with alternative therapy such as stenting, laser, atherectomy, cryoplasty, brachytherapy or re-entry devices
  • Significant target vessel tortuosity or other parameters prohibiting access to the target lesion
  • Presence of thrombus in the target vessel
  • Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤ 30 % residual diameter stenosis without death or major complications.
  • Presence of an aortic, iliac or femoral artificial graft.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (actual)
Patient registry
No

Groups and cohorts

  • DCB (Legflow .035") group

    treatment with Drug Coated Balloon angioplasty with the Legflow .035" Paclitaxel Balloon Dilatation catheter.

  • POBA group

    treatment with standard POBA (uncoated) angioplasty (type and brand at the physician's discretion)

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Endpoint:

    The primary efficacy endpoint is time to clinically-driven target lesion revascularization (CD-TLR) at 12 months, defined as any reintervention at the target lesion due to symptoms OR drop of ankle brachial index (ABI) \> 20 % OR ABI \> 0.15 compared to the post-procedural ABI.

    Time frame: 12 months post-procedure

  2. Device- and procedure-related death

    Primary Safety Endpoint: Freedom from device- and procedure-related death through 30 days post-index procedure;

    Time frame: 30 days post-procedure

  3. Major target limb amputation and clinically-driven target vessel revascularization

    Primary Safety Endpoint: A composite of (2.1) time to major target limb amputation (above-the-ankle (ATA)) through 12 months post-procedure and (2.2) time to clinically-driven target vessel revascularization (CD-TVR) through 12 months post-index procedure

    Time frame: 12 months post-procedure

Secondary outcomes

  1. Acute device success

    defined as successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure

    Time frame: during index procedure

  2. Acute procedural success

    Acute procedural success is defined as restoration of the target lesion with ≤30% residual stenosis in the final angiogram.

    Time frame: during index procedure

  3. Secondary safety endpoint at discharge up to 30 days post-index procedure

    Secondary safety endpoint is a composite of (3.1) freedom from all cause death (3.2) freedom from major target limb amputation (3.3) freedom from CD-TVR

    Time frame: 30 days post-operative

  4. Sustained clinical improvement at 6-, 12- and 24- months post-index procedure

    Clinical improvement is defined as a composite of (4.1) freedom from major target limb amputation, (4.2) freedom from TVR, (4.3) freedom from worsening target limb Rutherford class (compared to baseline) (4.4) freedom from decrease in target limb ankle brachial index (ABI) ≥0.15 (compared to baseline)

    Time frame: 6, 12, 24-months post-procedure

  5. Major Adverse Events (MAEs) at 6-, 12- and 24-months post-index procedure

    MAEs are defined as composite of (5.1) all-cause death, (5.2) CD-TVR (5.3) major target limb amputation (5.4) thrombosis at the target lesion

    Time frame: 6, 12, 24-months post-procedure

  6. Primary Patency at 6-, 12- and 24-months

    The primary patency is defined as a composite of (6.1) freedom from clinically-driven target lesion revascularization (CD-TLR) (6.2) freedom from binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis) • For discharge and 12-months: assessed by independent Core Lab

    Time frame: 6, 12, 24-months post-procedure

  7. Target Lesion Revascularization at 6-, 12- and 24-months post-index procedure

    defined as a reintervention to maintain or restore the patency in the target lesion. TLR is clinically-driven (CD) when the TLR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure.

    Time frame: 6, 12, 24-months post-procedure

  8. Target Vessel Revascularization at 6-, 12- and 24-months post-index procedure

    defined as a reintervention to maintain or restore the patency in the target vessel. TVR is clinically-driven (CD) when the TVR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure

    Time frame: 6, 12, 24-months post-procedure

  9. Binary restenosis at 6-, 12- and 24-months

    defined as a restenosis confirmed by DUS PSVR ≥2.4 or ≥50% stenosis (For 12-month: assessed by Independent Core-Lab)

    Time frame: 6, 12, 24-months post-procedure

  10. Major Target Limb Amputation at 6-, 12- and 24-months

    defined as an amputation above the ankle (ATA) in the target limb

    Time frame: 30- days, 6, 12, 24-months post-procedure

  11. Thrombosis at the target lesion at 6-, 12- and 24-months

    Thrombosis at the target lesion at 6-, 12- and 24-months

    Time frame: 6, 12, 24-months post-procedure

  12. All-cause death at 6-, 12- and 24-months

    All-cause death at 6-, 12- and 24-months

    Time frame: 30- days, 6, 12, 24-months post-procedure

  13. Change in target limb Rutherford Classification from baseline to 6-, 12- and 24-months

    Change in Target Limb Rutherford Classification from baseline to 6-, 12- and 24-months

    Time frame: 6, 12, 24-months post-procedure

  14. Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months

    Change in Target Limb Resting ABI or TBI from baseline to 6-, 12- and 24-months

    Time frame: 6, 12, 24-months post-procedure

  15. Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month.

    Improvement of life quality according to the Walking Impairment Questionnaire (WIQ) and the EQ-5D Questionnaire to baseline at follow-up at 6-, 12- and 24-month.

    Time frame: 6, 12, 24-months post-procedure

  16. device- and procedure-related death

    Freedom from device- and procedure-related death at discharge, 30 days, 6-, 12- and 24-months

    Time frame: 30- days, 6, 12, 24-months post-procedure

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 58 industry-sponsored observational studies under Peripheral Arterial Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 54 months is above that.

Counting every sponsor, half of 196 studies reached it within 36 months; a quarter within 22 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2021
First posted
Jul 21, 2021
StartActual
Jun 8, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2028
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04971772
Lead sponsor
Cardionovum GmbH
Collaborators
FCRE (Foundation for Cardiovascular Research and Education)
Responsible party
Sponsor
First posted
Jul 21, 2021
Start date
Jun 8, 2022
Primary completion
Dec 2026 (estimated)
Completion
Jan 2028 (estimated)
Last update
Mar 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion